查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462685

犬關節炎治療的全球市場預測（-2030）：按類型、治療類型、給藥途徑、通路和區域進行分析

Canine Arthritis Treatment Market Forecasts to 2030 - Global Analysis By Type, By Treatment Type, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

2023年全球犬關節炎治療市場規模為23億美元，預計2030年將達32億美元，預測期內年複合成長率為5.2%。犬關節炎治療包括多種控制關節炎犬疼痛和發炎的方法。

其中包括非類固醇消炎劑(NSAID) 等藥物、葡萄糖胺和軟骨素等補充品、物理治療、體重管理和生活方式改變。在嚴重的情況下，可能需要手術。目標是改善活動能力、減少不適並提高患者的生活品質。

根據美國寵物產品協會的數據，2017 年美國家庭中估計有 9,420 萬隻貓和 8,970 萬隻狗。

寵物擁有量和寵物醫療保健支出的增加

全球養寵物的趨勢不斷成長，對犬關節炎治療市場的成長做出了重大貢獻。隨著越來越多的人將寵物視為家庭的重要成員，寵物醫療保健的支出也相應增加，包括治療狗關節炎等疾病。寵物飼主越來越願意投資先進的醫療保健和療法，以確保寵物的健康和福祉，這推動了對創新治療方法的需求，並增加了整體市場的成長。

與先進治療方案相關的高成本

幹細胞療法和整形外科手術等先進治療方案的高昂費用給尋求犬類關節炎綜合治療的寵物飼主帶來了巨大的經濟障礙。這些先進的治療方法往往需要花費大量金錢，並且會阻礙患者接受治療。因此，寵物飼主可能會轉向更便宜的替代品，或者由於經濟限制而完全放棄治療。這種負擔能力的挑戰凸顯了對易於使用且具有成本效益的解決方案的需求，以確保為患有關節炎的寵物提供最佳護理。

對微創治療方案的需求不斷成長

寵物飼主擴大尋求微創手術，以提供更快的恢復時間並降低寵物出現併發症的風險。關節鏡和雷射治療等微創技術因其有效性和對寵物生活方式的影響極小而越來越受歡迎。這一趨勢為獸醫醫院和製造商提供了開發和提供創新的微創治療方法的機會，以滿足飼主及其患有關節炎的寵物不斷變化的需求。

與某些治療方法相關的潛在副作用和風險

非類固醇消炎劑(NSAID) 和皮質類固醇等治療可以緩解症狀，但也可能引起副作用，例如胃腸道問題和腎臟併發症。這些風險可能會阻止飼主選擇這些治療方法，並影響他們選擇傳統治療方法的意願。因此，確保犬關節炎治療的安全性和有效性對於減少對市場接受度和寵物福祉的潛在威脅至關重要。

COVID-19 的影響：

COVID-19 大流行改變了獸醫護理和寵物飼養行為，從而影響了犬類關節炎治療市場。對非必要服務的限制和經濟的不確定性減少了獸醫診所的就診次數，影響了診斷和治療。此外，財務限制影響寵物飼主投資先進治療的意願，影響市場成長並凸顯對負擔得起的治療選擇的需求。

非類固醇消炎劑（NSAID）部分預計在預測期內達到最大值

在預測期內，預計犬類關節炎治療市場將由非類固醇消炎劑（NSAID）領域主導。這種優越性歸因於多種因素，包括其廣泛用作治療狗關節炎相關疼痛和發炎的傳統治療選擇。此外，與其他先進治療方法相比，非類固醇消炎劑因其有效性和相對較低的成本而經常受到獸醫的青睞，從而使其佔據市場主導地位。

注射劑領域預計在預測期內年複合成長率最高

在犬關節炎治療市場中，注射劑市場預計將在預測期內實現最高成長。這種成長歸因於多種因素，包括給藥便利性、標靶治療的功效以及創新注射療法的開發。此外，配方技術的進步和向微創治療的轉變正在推動對注射劑的需求，並且是預計導致快速成長的因素。

比最大的地區

預計在預測期內，北美將主導犬類關節炎治療市場。這是由於寵物飼主數量眾多、可支配收入高、獸醫醫療基礎設施發達以及研發進步。此外，人們對寵物健康意識的增強以及像對待人類一樣對待寵物的趨勢也進一步促進了該地區的崛起。因此，在可預見的未來，北美預計將保持在犬類關節炎治療市場的主導地位。

年複合成長率最高的地區：

在預測期內，亞太地區的犬關節炎治療市場可望快速成長。這是由於寵物擁有量的增加、可支配收入的增加以及寵物保健意識的提高，這些都推動了對關節炎治療的需求。此外，獸醫基礎設施的改善和先進治療方法的採用正在提高治療的可及性。因此，亞太地區為市場擴張、吸引投資和促進犬關節炎治療解決方案的創新提供了重大機會。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球犬關節炎治療市場：依類型

  • 骨關節炎
  • 類風濕性關節炎
  • 幼年特發性關節炎

第6章全球犬關節炎治療市場：依治療類型

  • 非類固醇消炎劑(NSAID)
  • 緩解疾病抗風濕藥物 (DMARD)
  • 皮質類固醇
  • 營養補充食品
  • 物理治療與復健
  • 幹細胞療法
  • 外科手術
  • 其他治療類型

第7章全球犬關節炎治療市場：依給藥途徑

  • 口服
  • 注射
  • 局部的

第8章全球犬關節炎治療市場：按分銷管道

  • 動物診所/醫院
  • 零售藥房
  • 網路藥房

第9章全球犬關節炎治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第10章 主要進展

  • 協議、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Boehringer Ingelheim Animal Health
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health
  • Hill's Pet Nutrition
  • InVivo Therapeutics Corporation
  • Mars Petcare
  • Merck Animal Health
  • Norbrook Laboratories
  • Nutramax Laboratories, Inc.
  • OrthoPets LLC
  • Rejuvenate Bio
  • Royal Canin
  • Veterinary Orthopedic Implants Inc.
  • Vetoquinol SA
  • Virbac
  • Zoetis Inc.
Product Code: SMRC25736

According to Stratistics MRC, the Global Canine Arthritis Treatment Market is accounted for $2.3 billion in 2023 and is expected to reach $3.2 billion by 2030 growing at a CAGR of 5.2% during the forecast period. Canine arthritis treatment involves various approaches to managing pain and inflammation in dogs affected by arthritis. These may include medication such as nonsteroidal anti-inflammatory drugs (NSAIDs), supplements like glucosamine and chondroitin, physical therapy, weight management, and lifestyle modifications. In severe cases, surgery may be necessary. The goal is to improve mobility, reduce discomfort, and enhance the quality of life for affected dogs.

According to the American Pet Products Association, an estimated 94.2 million cats and 89.7 million dogs are owned by households in the U.S. during 2017.

Market Dynamics:

Driver:

Rising pet ownership and expenditure on pet healthcare

The increasing trend of pet ownership worldwide has significantly contributed to the growth of the canine arthritis treatment market. As more people embrace pets as integral members of their families, there's a corresponding rise in expenditure on pet healthcare, including treatment for conditions like canine arthritis. Pet owners are increasingly willing to invest in advanced medical care and therapies to ensure the health and well-being of their furry companions, driving demand for innovative treatments and boosting the overall market for canine arthritis treatment.

Restraint:

High cost associated with advanced treatment options

The high cost associated with advanced treatment options, such as stem cell therapy and orthopedic surgeries, presents a significant financial barrier for pet owners seeking comprehensive care for canine arthritis. These advanced treatments often entail substantial expenses, potentially deterring individuals from pursuing them. Consequently, pet owners may resort to less expensive alternatives or even forego treatment altogether due to financial constraints. This affordability challenge underscores the need for accessible and cost-effective solutions to ensure optimal care for pets suffering from arthritis.

Opportunity:

Growing demand for minimally invasive treatment options

Pet owners are increasingly seeking less invasive procedures that offer quicker recovery times and reduce the risk of complications for their furry companions. Minimally invasive techniques, such as arthroscopy and laser therapy, are gaining popularity due to their efficacy and minimal disruption to the pet's lifestyle. This trend presents an opportunity for veterinary clinics and manufacturers to develop and offer innovative, minimally invasive treatments to meet the evolving needs of pet owners and their arthritic pets.

Threat:

Potential side effects and risks associated with certain treatment modalities

Treatments like non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids can alleviate symptoms, but they may also lead to adverse reactions such as gastrointestinal issues or renal complications. Such risks may deter pet owners from pursuing these treatments, impacting their willingness to opt for conventional therapies. Consequently, ensuring the safety and efficacy of canine arthritis treatments is essential to mitigating potential threats to market acceptance and pet well-being.

Covid-19 Impact:

The COVID-19 pandemic has influenced the canine arthritis treatment market by altering veterinary care access and pet ownership behaviors. Restrictions on non-essential services and economic uncertainties have led to decreased veterinary visits, affecting diagnosis and treatment. Additionally, financial constraints have influenced pet owners' willingness to invest in advanced treatments, impacting market growth and emphasizing the need for affordable care options.

The nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to be the largest during the forecast period

In the canine arthritis treatment market, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment is projected to dominate during the forecast period. This dominance can be attributed to several factors, including their widespread use as a conventional treatment option for managing arthritis-related pain and inflammation in dogs. Additionally, NSAIDs are often preferred by veterinarians due to their efficacy and relatively low cost compared to other advanced treatment modalities, contributing to their anticipated prominence in the market.

The injectables segment is expected to have the highest CAGR during the forecast period

In the canine arthritis treatment market, the injectables segment is projected to experience the highest growth during the forecast period. This growth is attributed to several factors, including the convenience of administration, efficacy in delivering targeted treatment, and the development of innovative injectable therapies. Additionally, advancements in formulation technologies and a shift towards minimally invasive treatment options are driving the demand for injectables, contributing to their anticipated rapid growth trajectory.

Region with largest share:

Over the forecast period, North America is poised to dominate the canine arthritis treatment market. This is due to a large population of pet owners with high disposable income, a well-established veterinary healthcare infrastructure, and advanced research and development activities. Additionally, increasing awareness about pet health and a growing trend towards the humanization of pets further contribute to the region's prominence. Consequently, North America is expected to maintain its leading position in the canine arthritis treatment market in the foreseeable future.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is poised for rapid growth in the canine arthritis treatment market. This is due to increasing pet ownership rates, rising disposable incomes, and growing awareness of pet healthcare, which are driving demand for arthritis treatments. Additionally, improving veterinary infrastructure and the adoption of advanced treatment modalities are enhancing accessibility to care. As a result, the Asia-Pacific region presents significant opportunities for market expansion, attracting investments, and fostering innovation in canine arthritis treatment solutions.

Key players in the market

Some of the key players in Canine Arthritis Treatment Market include Boehringer Ingelheim Animal Health, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Hill's Pet Nutrition, InVivo Therapeutics Corporation, Mars Petcare, Merck Animal Health, Norbrook Laboratories, Nutramax Laboratories, Inc., OrthoPets LLC, Rejuvenate Bio, Royal Canin, Veterinary Orthopedic Implants Inc., Vetoquinol S.A., Virbac and Zoetis Inc.

Key Developments:

In February 2024, Rejuvenate Bio partnered with a leading animal health company to develop and commercialize groundbreaking gene therapy for canine osteoarthritis, aiming to address the condition's widespread prevalence and devastating consequences, potentially revolutionizing dog health. This agreement with the global company follows the agreement reached in 2022 with Phibro Animal Health and further validates the gene therapy technology developed by Rejuvenate Bio and their strategy to develop their breakthrough technology in both animal health and human health.

In May 2023, The Food and Drug Administration (FDA) approved Librela, for the control of canine OA pain in the U.S. The first and only injectable monoclonal antibody (mAb) treatment for canine OA is expected to be available in late 2023. A once-monthly injection administered by a veterinary professional, Librela (bedinvetmab injection) works differently than other pain medications, according to a May 5 release from Zoetis.

Types Covered:

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis

Treatment Types Covered:

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Corticosteroids
  • Nutraceuticals
  • Physical Therapy and Rehabilitation
  • Stem Cell Therapy
  • Surgery
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Injectables
  • Topical

Distribution Channels Covered:

  • Veterinary Clinics and Hospitals
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Canine Arthritis Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Osteoarthritis
  • 5.3 Rheumatoid Arthritis
  • 5.4 Juvenile Idiopathic Arthritis

6 Global Canine Arthritis Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.3 Disease-Modifying Antirheumatic Drugs (DMARDs)
  • 6.4 Corticosteroids
  • 6.5 Nutraceuticals
    • 6.5.1 "" Glucosamine

""

    • 6.5.2 Chondroitin
  • 6.6 Physical Therapy and Rehabilitation
  • 6.7 Stem Cell Therapy
  • 6.8 Surgery
  • 6.9 Other Treatment Types

7 Global Canine Arthritis Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectables
  • 7.4 Topical

8 Global Canine Arthritis Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Veterinary Clinics and Hospitals
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Canine Arthritis Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Boehringer Ingelheim Animal Health
  • 11.2 Ceva Sante Animale
  • 11.3 Dechra Pharmaceuticals PLC
  • 11.4 Elanco Animal Health
  • 11.5 Hill's Pet Nutrition
  • 11.6 InVivo Therapeutics Corporation
  • 11.7 Mars Petcare
  • 11.8 Merck Animal Health
  • 11.9 Norbrook Laboratories
  • 11.10 Nutramax Laboratories, Inc.
  • 11.11 OrthoPets LLC
  • 11.12 Rejuvenate Bio
  • 11.13 Royal Canin
  • 11.14 Veterinary Orthopedic Implants Inc.
  • 11.15 Vetoquinol S.A.
  • 11.16 Virbac
  • 11.17 Zoetis Inc.

List of Tables

  • Table 1 Global Canine Arthritis Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Canine Arthritis Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Canine Arthritis Treatment Market Outlook, By Osteoarthritis (2021-2030) ($MN)
  • Table 4 Global Canine Arthritis Treatment Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 5 Global Canine Arthritis Treatment Market Outlook, By Juvenile Idiopathic Arthritis (2021-2030) ($MN)
  • Table 6 Global Canine Arthritis Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 7 Global Canine Arthritis Treatment Market Outlook, By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
  • Table 8 Global Canine Arthritis Treatment Market Outlook, By Disease-Modifying Antirheumatic Drugs (DMARDs) (2021-2030) ($MN)
  • Table 9 Global Canine Arthritis Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 10 Global Canine Arthritis Treatment Market Outlook, By Nutraceuticals (2021-2030) ($MN)
  • Table 11 Global Canine Arthritis Treatment Market Outlook, By Glucosamine (2021-2030) ($MN)
  • Table 12 Global Canine Arthritis Treatment Market Outlook, By Chondroitin (2021-2030) ($MN)
  • Table 13 Global Canine Arthritis Treatment Market Outlook, By Physical Therapy and Rehabilitation (2021-2030) ($MN)
  • Table 14 Global Canine Arthritis Treatment Market Outlook, By Stem Cell Therapy (2021-2030) ($MN)
  • Table 15 Global Canine Arthritis Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 16 Global Canine Arthritis Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 17 Global Canine Arthritis Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 18 Global Canine Arthritis Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 19 Global Canine Arthritis Treatment Market Outlook, By Injectables (2021-2030) ($MN)
  • Table 20 Global Canine Arthritis Treatment Market Outlook, By Topical (2021-2030) ($MN)
  • Table 21 Global Canine Arthritis Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 22 Global Canine Arthritis Treatment Market Outlook, By Veterinary Clinics and Hospitals (2021-2030) ($MN)
  • Table 23 Global Canine Arthritis Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 24 Global Canine Arthritis Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.